WOAH Reference Laboratory Reports Activities 2023

Activities in 2023

This report has been submitted : 12 juillet 2024 06:36

Laboratory Information

Name of disease (or topic) for which you are a designated WOAH Reference Laboratory:	Bluetongue Virus
Address of laboratory:	5 Portarlington Road East Geelong Victoria 3219 Australia
Tel.:	+61-3 52 27 50 00
E-mail address:	debbie.eagles@csiro.au
Website:	https://www.csiro.au/en/about/facilities-collections/acdp
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Debbie Eagles, Director, Australian Centre of Disease Preparedness
Name (including Title and Position) of WOAH Reference Expert:	Dr Debbie Eagles, Director, Australian Centre of Disease Preparedness
Which of the following defines your laboratory? Check all that apply:	Governmental Research agency

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOAH Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
cELISA		254	13
Serum Neutralisation Test		181	13
Direct diagnostic tests		Nationally	Internationally
Real-Time PCR		253	0
Isolation		35	0
Isolate Typing by VNT		10	0
Capillary Sequencing		222	0
Whole Genome sequencing		9	0

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOAH?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
BTV Virus protein antigen	ELISA	Produce & Provide	2ml	0ml	1	AUSTRALIA,
BTV antiserum	ELISA	Produce & Provide	1ml	0ml	1	AUSTRALIA,
BTV Network Quality Control	ELISA	Produce & Provide	2ml	0ml	1	AUSTRALIA,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAH Members?

No

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAH Members?

Yes

NAME OF WOAH MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
SOLOMON (ISLANDS)	2023-05-01	ELISA + SNT	4	0
SOLOMON (ISLANDS)	2023-06-01	ELISA + SNT	9	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAH Member?

No

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAH Members other than the own?

No

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAH?

No

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:
Diagnostic testing and epidemiological data from national sentinel herd surveillance (as conducted under the National Arbovirus Monitoring Program). Diagnostic Testing includes serology, virus isolation and typing, sequencing and bioinformatics.

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:
Reports on sentinel herd surveillance are shared with member of National Arbovirus Monitoring Program; collated into an Annual Report (See 16d).

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

1
Validation of diagnostic tests for infectious diseases: challenges and opportunities, T. Reid; N. Singanallur Balasubramani; C. Waugh; T. Bowden; K. Newberry; A. Colling , International Symposium on Sustainable Animal Production and Health: Current Status and the Way Forward

c) National conferences:

d) Other (Provide website address or link to appropriate information):

1
National Animal Health Monitoring Program Annual Report, available at https://animalhealthaustralia.com.au/

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAH Members?

Yes

a) Technical visit : 52

b) Seminars : 15

c) Hands-on training courses: 37

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
A	INDONESIA	41
C	INDONESIA	25
C	PAPUA NEW GUINEA	1
B	INDONESIA	15
A	PAPUA NEW GUINEA	11

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO9001	Attached	FS 605099 - 001.pdf

ISO14001	Attached	EMS 605098 - 001.pdf
ISO17025	Attached	NATA ISO 17025 APR 2024.pdf
ISO17043	Attached	NATA ISO 17043 NOV 2022.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
BTV Isolation	NATA (ISO 17025)
BTV PCR	NATA (ISO 17025)
BTV VNT	NATA (ISO 17025)
BTV Taqman	NATA (ISO 17025)
BTV SNT	NATA (ISO 17025)
BTV cELISA	NATA (ISO 17025)
BTV Antigen ELISA	NATA (ISO 17025)

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

The laboratory has a dedicated Biorisk Management Team (18 Members) who provide specialist advice, monitor and improve Biosafety, Biosecurity and Biocontainment activities and perform maintenance and validaition on Biocontainment systems. The team uses a risk analysis approach to the management of biological risks for biosafety and biosecurity to inform and determine the policy and procedures that, in turn, give confidence that the laboratory procedures for each of the biological materials handled by the laboratory pose a negligible danger to Australia's animal and human populations. 261 Policies and procedures are contained in the annually reviewed ACDP Biorisk Manual, which consists of various sections as follows. Section 1 Administration; Section 2 PC2 Procedures and Policies; Section 3 PC3 Procedures and Policies; Section 4 PC4 Procedures and Policies; Section 5 Large Animal Facility (LAF) Procedures and Policies; Section 6 Personnel and Procedural Controls; Section 7 Transport and Storage of Biological Material; Section 8 Movement of Material, Equipment and Waste; Section 9 Engineering Procedures and Polices; Section 10 Microbiological Incident Response Procedures and Policies; Section 11 Laboratory Services Group; Section 12 Containment Services Group. The successful ACDP biological risk management system has clear and unequivocal commitment by laboratory management, who ensure that roles, responsibilities, resources and authorities related to biological risk management are defined, documented, and communicated to those who manage, perform, and verify work associated with biological agents and toxins in the laboratory. In addition to statutory monitoring and audits from regulatory authorities, the Biorisk Management Team facilitate an inspection across three days every six months by an external security assessment team to provide an independent review of elements affecting ACDP's microbiological and physical security operations with findings communicated to CSIRO senior executive management of any areas of concern or risk. The laboratory aspires to become accredited to ISO 35001:2019 Biorisk management for laboratories and other related organisations.

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAH?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAH?

No

TOR10: NETWORK WITH WOAH REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAH Reference Laboratories designated for the same pathogen or disease?

Yes

24. Do you network (collaborate or share information) with other WOAH Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAH Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAH Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAH Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons1	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the Test	WOAH Member Countries
Provision of PT for state jurisdictional laboratories in Australia (LEADDR) for detection of BTV by PCR	Organiser and participant	8	PCR	AUSTRALIA,

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAH?

Yes

KIND OF CONSULTANCY	Location	SUBJECT (FACULTATIVE)
Technical advice	Virtual	Coordinated feedback from all BTV reference laboratories on test validation template

29. Additional comments regarding your report: